Genetic Technologies Ltd ADR (GENE)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| CEO: | Simon Morriss |
| Employees: | 50 |
| Web site: | genetype.com |
|
SUITE 7, LEVEL 1, 321 CHAPEL STREET, PRAHRAN VICTORIA, C3, 3181
011613-9415-1135
| |
-
Formally known as:
- Genetic Technologies Ltd
| Date | Ratio |
|---|---|
| 2015-01-20 | 1:5 |
| 2019-08-15 | 1:4 |
| 2023-12-14 | 1:5 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Genetic Technologies Limited provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. Its lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company also develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma.
Please log in first to see chart